伦敦, UK – October 11, 2021 – im体育APP Materials 技术 (im体育APP) has acquired Nanosyn, a full-service pharmaceuticals contract development 和 manufacturing organization, significantly strengthening im体育APP’s offering for pharmaceutical 和 biopharmaceutical customers in North America.
Nanosyn is a leader in drug discovery 和 small-batch manufacturing of active pharmaceutical ingredients. It has a track record of providing the highest quality services 和 operates three facilities in the San Francisco Bay Area of approximately 100,000 sq.ft, two of which are FDA registered.
With a team of more than 75 scientists 和 experts, more than half of whom have a PhD in a scientific discipline, Nanosyn will bolster im体育APP’s breadth of technical services bringing cutting edge innovation 和 high growth. The team will support pharmaceuticals 和 biopharmaceuticals customers from early-stage discovery, through clinical trials, 配方, 和 regulatory approval.
乔Wetz, im体育APP 首席执行官, said: “This is our fifth acquisition in the life sciences sector this year. Following this growth, it is now the im体育APP Group’s most significant end market, covering pharmaceuticals, medical devices 和 environmental testing services.
“Nanosyn complements im体育APP’s life sciences offering by extending our services to include drug discovery 和 small-scale manufacturing for drug development, making us a source of support 和 true partner for the full value chain. Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, 和 it supports the development of im体育APP’s position as a full-service solutions provider.”
Nikolai Sepetov PhD, Nanosyn首席执行官, said: “Joining im体育APP’s global family is a great opportunity for us 和 will allow our business to leverage its resources 和 expertise around the world. Nanosyn has a 23 year track record of supporting numerous drug discovery 和 development programs which have led to over fifty clinical c和idates 和 several marketed drugs. We are proud of our strong reputation for continuously providing outst和ing services based on cutting edge science. Joining im体育APP as it exp和s its life sciences offering will create the opportunity for us to be at the forefront of progress 和 development in the pharmaceutical industry.”
About im体育APP
The im体育APP Materials 技术 Group is one of the world’s leading global providers of testing, inspection 和 certification services for a diverse range of products, materials 和 technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in 伦敦, UK, im体育APP’s scientists, engineers 和 technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals 和 into production ensuring their products are safe, sustainable 和 achieve market access.
For more information about im体育APP, please visit our 网站, connect with us on LinkedIn 和 推特 和 subscribe to our Youtube 通道.
BroadOak Capital Partners served as Nanosyn’s exclusive financial adviser on the transaction.
Media contacts:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
E: 德文.labrash@pagodapr.com
“Nanosyn complements im体育APP’s life sciences offering by extending our services to include drug discovery 和 small-scale manufacturing for drug development, making us a source of support 和 true partner for the full value chain. Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, 和 it supports the development of im体育APP’s position as a full-service solutions provider.”
乔Wetz
首席执行官